Media & Events

Cell BioEngines Joins the BARDA VITAL Biotech Accelerator Companies Developing Cutting-edge Therapeutics

Cell BioEngines Founder Joins Panel at Nucleate New York Activator 5.0 Demo Day

Cell BioEngines Officially Graduated from Endless Frontier Labs (EFL) Life Sciences Cohort 2025-26

Cell BioEngines Exhibited at Delaware BioScience Association's DNA 2026 Annual Conference

Cell BioEngines Expands its Cell and Gene Therapy R&D Headquarters in Wilmington, Delaware

Cell BioEngines Accepted into NVIDIA Inception Program for Startups to Build AI‑driven HLA compatibility platform

Founder and CEO, Dr. Ajay Vishwakarma featured on Builds Bio 2025 Quarterly Newsletter

Cell BioEngines Announces Establishment of New Facility in New York at CEPM

Cell BioEngines, Inc: Oncology Startup Chosen for Inaugural SCbioDrive Accelerator Program

Cell BioEngines Secures $2 Million in Funding From SOSV and New York Ventures

Cell BioEngines to Present at the 2024 BIO CEO & Investor Conference in New York

SOSV-backed Biotech Firm Cell BioEngines Decides New York Is the Place to Be

Cell BioEngines Enters Agreement with Miltenyi Biotec to Manufacture Allogeneic Matched Transgene-free HSCT

Cell BioEngines Licenses Patent for Allogeneic Hematopoietic / Blood Stem Cell Transplantation in Oncology

Cell BioEngines Enters into an Exclusive Worldwide Agreement to Develop and Commercialize Rare Immune Cells